Skip to main content

Search
Profile

Julia Emerson, MD, MPH

|
Julia Emerson, MD, MPH

Research Center: Center for Clinical and Translational Research

Overview

Research Focus Area

Translational Research

Publications

Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.
Pediatric pulmonology , 2010 Sep: 934-44
Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
Pediatric pulmonology , 2010 Apr: 363-70
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
Pediatric pulmonology , 2010 Feb: 127-34
Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.
The Journal of pediatrics , 2009 Nov: 634-9.e1-4
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Contemporary clinical trials , 2009 May: 256-68
Pseudomonas aeruginosa Type III secretion system interacts with phagocytes to modulate systemic infection of zebrafish embryos.
Cellular microbiology , 2009 Feb 6
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
The Journal of pediatrics , 2009 Feb: 183-8
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2009 Jan: 66-70
Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.
The Journal of infectious diseases , 2007 Oct 1: 1088-92
Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study.
Chest , 2007 Oct: 1212-8
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
Pediatric pulmonology , 2007 Jul: 610-23
Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa.
Proceedings of the National Academy of Sciences of the United States of America , 2006 Dec 26: 19890-5
Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.
Human gene therapy , 2006 Apr: 440-7
Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection.
The Journal of antimicrobial chemotherapy , 2005 Nov: 879-86
Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
Journal of clinical microbiology , 2004 May: 1915-22
Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials.
Pediatric pulmonology , 2004 May: 385-92
Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis.
Journal of clinical microbiology , 2003 Sep: 4312-7
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
American journal of respiratory and critical care medicine , 2003 Mar 15: 841-9
Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis.
Chest , 2003 Mar: 792-9
Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.
American journal of respiratory and critical care medicine , 2002 Dec 15: 1550-5
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
Pediatric pulmonology , 2002 Aug: 91-100

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options